A decade of tau transgenic animal models and beyond

Jürgen Götz*, Natasha Deters, Amy Doldissen, Laita Bokhari, Yazi Ke, Andreas Wiesner, Nicole Schonrock, Lars M. Ittner

*Corresponding author for this work

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

The first tau transgenic mouse model was established more than a decade ago. Since then, much has been learned about the role of tau in Alzheimer's disease and related disorders. Animal models, both in vertebrates and invertebrates, were significantly improved and refined as a result of the identification of pathogenic mutations in Tau in human cases of frontotemporal dementia. They have been instrumental for dissecting the cross-talk between tau and the second hallmark lesion of Alzheimer's disease, the Aβ peptide-containing amyloid plaque. We discuss how the tau models have been used to unravel the pathophysiology of Alzheimer's disease, to search for disease modifiers and to develop novel treatment strategies. While tau has received less attention than Aβ, it is rapidly acquiring a more prominent position and the emerging view is one of a synergistic action of Aβ and tau in Alzheimer's disease. Moreover, the existence of a number of neurodegenerative diseases with tau pathology in the absence of extracellular deposits underscores the relevance of research on tau.

Original languageEnglish
Pages (from-to)91-103
Number of pages13
JournalBrain Pathology
Volume17
Issue number1
DOIs
Publication statusPublished - 1 Jan 2007
Externally publishedYes

Fingerprint Dive into the research topics of 'A decade of tau transgenic animal models and beyond'. Together they form a unique fingerprint.

  • Cite this